Vista Investment Partners LLC Buys 6,091 Shares of Medtronic PLC $MDT

Key Points

• Vista Investment Partners LLC significantly increased its stake in Medtronic PLC by 64.0%, purchasing an additional 6,091 shares, bringing their total holdings to 15,607 shares valued at approximately $1.36 million.
• Corporate insiders displayed mixed activity, with EVP Harry Skip Kiil selling 8,605 shares, reducing his stake by 19.46%, while Director William R. Jellison purchased 2,500 shares, increasing his holdings by 100%.
• Medtronic reported a 7.7% year-over-year revenue increase for the latest quarter, with earnings per share surpassing expectations at $1.26, and set guidance for FY 2026 at $5.600-$5.660 EPS.

Vista Investment Partners LLC raised its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 64.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 15,607 shares of the medical technology company's stock after acquiring an additional 6,091 shares during the quarter. Vista Investment Partners LLC's holdings in Medtronic were worth $1,360,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Vanguard Group Inc. increased its position in shares of Medtronic by 0.7% during the first quarter. Vanguard Group Inc. now owns 125,014,241 shares of the medical technology company's stock worth $11,233,780,000 after buying an additional 810,854 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Medtronic by 7.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 22,278,023 shares of the medical technology company's stock worth $2,001,903,000 after buying an additional 1,461,841 shares during the period. Bank of New York Mellon Corp grew its holdings in Medtronic by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 20,680,301 shares of the medical technology company's stock worth $1,858,332,000 after purchasing an additional 756,192 shares during the period. Deutsche Bank AG grew its holdings in Medtronic by 3.1% in the first quarter. Deutsche Bank AG now owns 19,009,795 shares of the medical technology company's stock worth $1,708,220,000 after purchasing an additional 566,155 shares during the period. Finally, Invesco Ltd. grew its holdings in Medtronic by 9.9% in the first quarter. Invesco Ltd. now owns 16,980,592 shares of the medical technology company's stock worth $1,525,876,000 after purchasing an additional 1,535,308 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medtronic news, Director William R. Jellison acquired 2,500 shares of the stock in a transaction dated Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.26% of the company's stock.

Medtronic Price Performance

Medtronic stock traded up $0.17 during mid-day trading on Monday, hitting $95.25. 2,257,998 shares of the company traded hands, compared to its average volume of 7,607,601. Medtronic PLC has a one year low of $79.29 and a one year high of $96.25. The stock has a market cap of $122.18 billion, a price-to-earnings ratio of 26.24, a price-to-earnings-growth ratio of 2.50 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The stock has a fifty day moving average price of $92.05 and a 200-day moving average price of $88.29.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic's payout ratio is presently 78.24%.

Analyst Ratings Changes

A number of research firms have commented on MDT. Mizuho raised their price target on shares of Medtronic from $98.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Wall Street Zen upgraded shares of Medtronic from a "hold" rating to a "buy" rating in a report on Saturday, August 30th. Sanford C. Bernstein raised their price target on shares of Medtronic from $97.00 to $98.00 and gave the stock an "outperform" rating in a report on Wednesday, August 20th. Robert W. Baird raised their price objective on shares of Medtronic from $94.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, August 20th. Finally, William Blair raised shares of Medtronic to a "hold" rating in a research note on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus price target of $102.27.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.